I now rate Recursion Pharma a sell due to disappointing ... RXRX also reports the non-GAAP cash burn figure of $118M, taking out $16M of transaction costs and adding in $2M for the purchase ...

Financially, the merger would roll all outstanding Ainnova equity into the publicly traded company, avoiding cash dilution and aligning incentives for the combined team. Leadership has signaled that ...

Baystreet.ca News Commentary – Momentum continues to build behind AI in healthcare, as capital finds its way to technologies capable of reshaping how care is delivered, diagnosed, ...

While semantic search methods that directly explain examples by ... inductively transform non-recursive sentences with invented predicates into recursive sentences. We analyze MPL language’s ...

OpenAI’s newest creation, the o3 model—billed as their “smartest and most capable to date”—rebelled against direct commands to shut itself down. This incident ignited a firestorm of unease, with Elon ...

Recursive neural networks are connectionist models capable of solving supervised and non-supervised learning problems represented by directed ordered acyclic graphs. The potential of this novel ...

hash tables), Recursive and non-recursive algorithms (searching and sorting, tree and graph traversal). Abstract data types, inheritance. Control and scheduling of large information processing systems ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical ...

After layoffs at Recursion, the company’s CEO writes about taking inspiration from an unexpected source: “The Art of Racing ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.